Raheel Ahmed

Dr. Raheel Ahmed


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2025 in Journal of Cardiac Failure
Verified
Journal Article
Open access
SWSaad Ahmed Waqas
Saad Ahmed Waqas
MSMuhammad Umer Sohail
Muhammad Umer Sohail
MSMuhammad Saad
Muhammad Saad
AMAbdul Mannan Khan Minhas
Abdul Mannan Khan Minhas
SGStephen J. Greene
Stephen J. Greene
RARaheel Ahmed
Raheel Ahmed
Heart failure with mildly reduced or preserved ejection fraction (HFpEF) accounts for over half of heart failure cases, with obesity playing a key role. Residual risk remains high despite available therapies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential cardiometabolic benefits, but their role in HFpEF remains unclear. A systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GLP-1RAs in HFpEF was conducted. Studies evaluating GLP-1RA in combination with glucose-dependent insulinotropic polypeptide (GIP) were also included. The analyzed outcomes included cardiovascular (CV) death, worsening heart failure (HF) events, and their composite. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Six RCTs with 8,788 patients were included. GLP-1RAs significantly reduced the composite outcome of CV death or worsening HF events (HR: 0.68 [0.51-0.89], p = 0.006, I² = 47%) as well as worsening HF events alone (HR: 0.56 [0.38-0.82], p = 0.003, I² = 51%). No significant reduction was observed for CV death alone (HR: 0.86 [0.67-1.12], p = 0.27, I² = 0%). GLP-1RAs reduce worsening HF events and the composite of CV death or worsening HF in HFpEF, particularly in patients with obesity or diabetes. These findings support their role as a promising therapy requiring further HFpEF-focused trials.

10 January 2025 in Heart & Lung
Verified
Journal Article
Open access
DADua Ali
Dua Ali
SQShaheer Qureshi
Shaheer Qureshi
HSHibah Siddiqui
Hibah Siddiqui
MUMuhammad Salik Uddin
Muhammad Salik Uddin
SWSaad Ahmed Waqas
Saad Ahmed Waqas
RARaheel Ahmed
Raheel Ahmed
Obstructive sleep apnea (OSA) prevalence has risen significantly, affecting millions globally and posing a major healthcare burden. OSA is strongly associated with cardiovascular diseases (CVD) such as heart failure, stroke, and ischemic heart disease. However, trends in CVD-related mortality among individuals with OSA remain underexplored. This study aims to assess the trends of OSA and CVD related mortality rates and variations in mortality based on demographics and regions in the US. Mortality data for adults aged ≥25 with OSA and CVD were extracted from the CDC WONDER database. Age-adjusted mortality rates (AAMRs) per 100,000 and annual percent change (APC) with 95 % confidence intervals (CIs) were calculated, stratified by year, sex, race/ethnicity, age, urbanization, and Census regions. Between 1999 and 2019, 168,111 OSA-related CVD deaths were recorded. Overall AAMRs rose significantly, particularly for hypertensive disease (1999-2006 APC: 13.2 %, 95 % CI: 11.6-15.7). Men consistently had higher AAMRs than women, and Black individuals showed the highest racial disparities. AAMRs varied geographically, with the Midwest recording the highest rates and rural areas showing notable increases. States like Oregon and Montana had rates three times higher than New York and Massachusetts. OSA-related CVD mortality has risen substantially, with marked disparities by sex, race, and region. These findings emphasize the need for targeted public health interventions to reduce mortality in high-risk groups.

7 November 2023 in European Journal of Heart Failure
Verified
Journal Article
Open access
VKVasileios Kouranos
Vasileios Kouranos
RKRajdeep S. Khattar
Rajdeep S. Khattar
JOJoseph Okafor
Joseph Okafor
RARaheel Ahmed
Raheel Ahmed
AAAlessia Azzu
Alessia Azzu
RSRakesh Sharma
Rakesh Sharma
Aims: Cardiac sarcoidosis (CS) is a potentially fatal condition that varies in its clinical presentation. Here, we describe baseline characteristics at presentation along with prognosis and predictors of outcome in a sizable and deeply phenotyped contemporary cohort of CS patients. Methods and results: Consecutive CS patients seen at one institution were retrospectively enrolled after undergoing laboratory testing, electrocardiogram, echocardiography, cardiac magnetic resonance (CMR) imaging and 18F-flourodeoxyglucose positron emission tomography (FDG-PET) at baseline. The composite endpoint consisted of all-cause mortality, aborted sudden cardiac death, major ventricular arrhythmic events, heart failure hospitalization and heart transplantation. A total of 319 CS patients were studied (67% male, 55.4 ± 12 years). During a median follow-up of 2.2 years (range: 1 month–11 years), 8% of patients died, while 33% reached the composite endpoint. The annualized mortality rate was 2.7% and the 5- and 10-year mortality rates were 6.2% and 7.5%, respectively. Multivariate analysis showed serum brain natriuretic peptide (BNP) levels (hazard ratio [HR] 2.41, 95% confidence interval [CI] 1.34–4.31, p = 0.003), CMR left ventricular ejection fraction (LVEF) (HR 0.96, 95% CI 0.94–0.98, p < 0.0001) and maximum standardized uptake value of FDG-PET (HR 1.11, 95% CI 1.04–1.19, p = 0.001) to be independent predictors of outcome. These findings remained robust for different patient subgroups. Conclusion: Cardiac sarcoidosis is associated with significant morbidity and mortality, particularly in those with cardiac involvement as the first manifestation. Higher BNP levels, lower LVEF and more active myocardial inflammation were independent predictors of outcomes.

19 December 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
MAMushood Ahmed
Mushood Ahmed
ANAbdullah Nofal
Abdullah Nofal
ASAimen Shafiq
Aimen Shafiq
HJHira Javaid
Hira Javaid
AAAreeba Ahsan
Areeba Ahsan
GFGregg C. Fonarow
Gregg C. Fonarow
Background: The prevalence of type 2 diabetes (T2D) and obesity are increasing in the United States. However, population‐level data for mortality trends due to T2D and obesity are limited. This study aims to assess these death trends among adults in the United States categorized by sex, race, and geographical location.Methods: We queried the CDC‐WONDER database for multiple cause of death data of adults aged ≥25 years. The crude mortality rates (CMR), age‐adjusted mortality rates (AAMRs), annual percent change (APC), and the average APC (AAPC) along with a 95% confidence interval (CI) were analyzed.Results: From 1999 to 2022, a total of 88,597 T2DM and obesity‐related deaths were recorded in the United States. The AAMR consistently increased from 1999 to 2017 (APC: 7.64; 95% CI: 1.91–9.96), followed by a marked rise from 2017 to 2022 (APC: 20.13; 95% CI: 12.88–38.57). The AAMR was approximately 3.58 times higher during the COVID‐19 pandemic compared to the period from 1999 to 2019. The AAMR for males was consistently greater than that for females. The highest AAMR was observed in non‐Hispanic (NH) Blacks or African Americans, followed by NH White, Hispanic or Latino, and other NH populations. Rural areas (AAMR: 1.86, 95% CI: 1.83–1.89) exhibited a greater AAMR than urban regions 1.26 (95% CI: 1.25–1.27).Conclusions: Our results indicate a substantial increasing trend of T2D and obesity‐related deaths in the United States especially during the COVID‐19 pandemic.

11 December 2024 in Life Sciences
Verified
Journal Article
Closed access
FLFakhar Latif
Fakhar Latif
AMAyesha Mubbashir
Ayesha Mubbashir
MKMuhammad Sohaib Khan
Muhammad Sohaib Khan
ZSZain Shaikh
Zain Shaikh
AMAaima Memon
Aaima Memon
SKSai Gautham Kanagala
Sai Gautham Kanagala

11 March 2024 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
JOJoseph Okafor
Joseph Okafor
RKRajdeep Khattar
Rajdeep Khattar
VKVasileios Kouranos
Vasileios Kouranos
SOShreya Ohri
Shreya Ohri
DDDavide Diana
Davide Diana
KWKshama Wechalekar
Kshama Wechalekar